Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05557877
Other study ID # MC220301
Secondary ID NCI-2022-07430MC
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 14, 2023
Est. completion date January 30, 2027

Study information

Verified date June 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) patients with benign breast disease planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.


Description:

PRIMARY OBJECTIVE: I. Pre- versus (vs) post-intervention change in postpartum-related breast cancer (PRBC) score. SECONDARY OBJECTIVE: I. Pre- vs. post-intervention change in postpartum involution (PPI) signature score. EXPLORATORY OBJECTIVES: I. Pre- vs. post-intervention change in percent of epithelial cells positive for COX-2, estrogen receptor (ER)/Ki67, gammaH2AX, and p16 in "normal" and in benign breast disease (BBD) lobule. II. Pre- vs. post-intervention change in serum C-reactive protein (CRP), estrogens, insulin/insulin-like growth factors (IGFs), and adipokines. III. Pre- vs. post-intervention changes in tissue and urine prostaglandins (PGs) and PGE2. OUTLINE: Patients undergo standard of care breast biopsy for assessment of abnormalities seen on imaging, as well as collection of blood during screening. If cancer is found, patient is taken off study and treatment options are discussed with treating physician. Patients without a cancer finding on biopsy then receive low-dose aspirin orally (PO) daily and undergo collection of blood on study. Patients may undergo ultrasound guided breast biopsy as clinically indicated.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date January 30, 2027
Est. primary completion date January 30, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - PRE-REGISTRATION: Age >= 18 years and =< 45 years of age - PRE-REGISTRATION: Presence of lesion suspicious for benign breast disease and planned breast biopsy or planned mammoplasty or other breast surgery (e.g., breast reduction, breast implants, etc.) or willing to have research biopsy or breast biopsy = 12 months prior to pre-registration for benign breast disease with tissue available for research. - PRE-REGISTRATION: Had a live birth =< 10 years prior to pre-registration - PRE-REGISTRATION: Pre-menopausal according to patient report and/or clinical determination - PRE-REGISTRATION: Provide written informed consent - PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance - PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research - PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research - REGISTRATION: Age >= 18 years and =< 45 years of age - REGISTRATION: Histological confirmation of benign breast disease (i.e., no evidence of DCIS or invasive cancer) - REGISTRATION: Registration for this study must be completed either =< one (1) year after the qualifying pre-registration biopsy performed for this study or =< one (1) year after collection of the archived tissue (for those who did not have a pre-registration biopsy performed after pre-registration for this study) - REGISTRATION: Hemoglobin >= 9.0 g/dL (obtained =< 30 days prior to registration) - REGISTRATION: Platelet count >= 100,000/mm^3 (obtained =< 30 days prior to registration - REGISTRATION: Serum creatinine =< 2.0 mg/dl (obtained =< days prior to registration) - REGISTRATION: Negative pregnancy test done =< 14 days prior to registration - REGISTRATION: Willing to use contraception while on treatment - REGISTRATION: Provide written informed consent - REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance - REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research - REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research - REGISTRATION: Willing to return to enrolling institution for follow-up - REGISTRATION: Known or suspected active breast infection Exclusion Criteria: - PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS) - PRE-REGISTRATION: Received systemic treatment for any other cancer at any time - PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =< 5 days prior to pre-registration and no more than eight doses within =< 30 days prior to pre-registration) - PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer - PRE-REGISTRATION: Currently taking anticoagulants - PRE-REGISTRATION: Contraindication for aspirin use - PRE-REGISTRATION: Known or suspected active breast infection - REGISTRATION: No research tissue available from pre-registration biopsy or from archived tissue (collected =< 12 months prior to pre-registration) - REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =< 5 days prior to registration and no more than four doses within =< 30 days prior to registration) - REGISTRATION: Co-morbid illnesses/conditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens - REGISTRATION: Any contraindication to aspirin use including but not limited to: - Bleeding disorders (e.g., hemophilia) - Stomach or intestinal bleeding =< 6 months prior to registration - Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs) - REGISTRATION: Currently taking anticoagulants - REGISTRATION: Any prior or current malignancy requiring prior or current systemic therapy - REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days - REGISTRATION: Post-menopausal: - Prior bilateral surgical oophorectomy or - No menses for > 1 year with estradiol levels within postmenopausal range, according to institutional standard - Known or suspected active breast infection

Study Design


Intervention

Procedure:
Biospecimen Collection
Undergo collection of blood
Drug:
Low-Dose Aspirin
Given PO
Other:
Questionnaire Administration
Ancillary studies
Procedure:
Ultrasound-Guided Biopsy
Undergo ultrasound-guided breast biopsy

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (2)

Lead Sponsor Collaborator
Mayo Clinic National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in percent of epithelial cells positive for COX-2, estrogen receptor (ER)/Ki67, gammaH2AX, and p16 in "normal" and in benign breast disease (BBD) lobules Will be calculated based on pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in PPI signature will be assessed using a Pearson correlation if both the scores are normally distributed. If either score is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. Pre- vs. post-intervention up to 30 days
Other Change in serum C-reactive protein (CRP), estrogens, insulin/insulin-like growth factors (IGFs), and adipokines Will be measured pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in the respective serum measures will be assessed using a Pearson correlation if both the values are normally distributed. If either value is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. Pre- vs. post-intervention up to 30 days
Other Changes in tissue and urine prostaglandins (PGs) and PGE2 Will be measured pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in the respective PGs will be assessed using a Pearson correlation if both the values are normally distributed. If either value is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. Pre- vs. post-intervention up to 30 days
Primary Change in pregnancy-related breast cancer (PRBC) score Will transform the biomarkers using Van der Waerden rank transformations. Will analyze data as within person differences for pre- versus post-treatment PRBC scores in tissues. The final mean difference in PRBC score point estimate and corresponding 95% confidence interval will be reported. Pre- versus (vs) post-intervention up to 30 days
Secondary Change in postpartum involution (PPI) signature score Will be calculated pre- and post-intervention for each person. Within person differences will be analyzed. The correlation between the change in PRBC score and change in PPI signature will be assessed using a Pearson correlation if both the scores are normally distributed. If either score is non-normally distributed, a Spearman correlation will be used instead. The correlation coefficient point estimate and 95% confidence interval will be reported. Pre- vs. post-intervention up to 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04996316 - MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Completed NCT05526872 - A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening N/A
Not yet recruiting NCT05178498 - Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Recruiting NCT01462903 - A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase 1
Completed NCT01422408 - Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy Phase 2
Terminated NCT02810873 - Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer N/A
Terminated NCT00770354 - Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer Phase 2
Withdrawn NCT03185871 - Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses Phase 2
Completed NCT02983279 - Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT05406232 - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Recruiting NCT03408353 - Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study
Completed NCT01641068 - Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms N/A
Withdrawn NCT04190433 - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Phase 2
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Terminated NCT02923037 - Hatha Yoga in Breast Cancer Survivors N/A

External Links